跳转至内容
Merck
CN
  • Synergistic apoptosis following endoplasmic reticulum stress aggravation in mucinous colon cancer.

Synergistic apoptosis following endoplasmic reticulum stress aggravation in mucinous colon cancer.

Orphanet journal of rare diseases (2020-08-20)
Ashok K Dilly, Brendon D Honick, Yong J Lee, David L Bartlett, Haroon A Choudry
摘要

Mucinous colon cancers (MCC) are characterized by abundant production of mucin 2 (MUC2) protein and are less sensitive to standard systemic chemotherapy. We postulated that severe/persistent endoplasmic reticulum stress (ERS) aggravation in MCC would overwhelm compensatory cytoprotective pathways and induce apoptosis. Basal levels of ERS markers were higher in MCC and dnTCF-LS174T cells than non-mucinous tumors and these levels were significantly increased by combinatorial treatment with ERS aggravators celecoxib + orlistat. Combination treatment inhibited cell viability and synergistically induced apoptosis. Treatment-induced cell death was ERS-dependent, apoptotic pathways were not activated following knockdown of ERS protein CHOP. Dual drug treatment significantly reduced mucinous tumor growth in vivo and induced ERS and apoptosis, consistent with in vitro experiments. Novel therapies are needed since MCC are more resistant to standard systemic chemotherapy. This study suggests ERS aggravation is a viable therapeutic strategy to reduce tumor growth in MCC.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
抗 β-肌动蛋白抗体,小鼠单克隆, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
N -乙基马来酰亚胺, crystalline, ≥98% (HPLC)
Sigma-Aldrich
羟胺 盐酸盐, 99.995% trace metals basis
Sigma-Aldrich
MISSION® esiRNA, targeting human DDIT3